País: Irlanda
Idioma: inglés
Fuente: HPRA (Health Products Regulatory Authority)
Paracetamol; Pseudoephedrine
PCO Manufacturing Ltd.
N02BE; N02BE51
Paracetamol; Pseudoephedrine
500 mg/30 milligram(s)
Tablet
Product not subject to medical prescription
Anilides; paracetamol, combinations excl. psycholeptics
Authorised
2006-09-08
_ _ _ _ _ _ PACKAGE LEAFLET: INFORMATION FOR THE USER NON-DROWSY SINUTAB ® TABLETS PARACETAMOL 500 MG PSEUDOEPHEDRINE HYDROCHLORIDE 30 MG READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Always use this medicine exactly as described in this leaflet or as your doctor or pharmacist have told you. Keep this leaflet. You may need to read it again. Ask your pharmacist if you need more information or advice. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. You must talk to a doctor if you do not feel better or if you feel worse after 5 days WHAT IS IN THIS LEAFLET 1. What Non-Drowsy Sinutab Tablets is and what it is used for 2. What you need to know before you use Non-Drowsy Sinutab Tablets 3. How to use Non-Drowsy Sinutab Tablets 4. Possible side effects 5. How to store Non-Drowsy Sinutab Tablets 6. Contents of the pack and other information 1. WHAT NON-DROWSY SINUTAB TABLETS IS AND WHAT IT IS USED FOR Non-Drowsy Sinutab relieves the symptoms of colds and flus including aches, pains, fever, nasal and sinus congestion. The tablets contain paracetamol, an analgesic and antipyretic to relieve pain and fever, and pseudoephedrine, a decongestant to clear nasal congestion and blocked sinuses. This medicine is for use in adults and children aged 12 years and over. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE NON-DROWSY SINUTAB TABLETS This medicine is suitable for most people but a few people should not use it. If you are in any doubt, talk to your doctor or pharmacist. DO NOT USE THIS MEDICINE… If you have ever had a BAD REACTION (ALLERGIC REACTION) to PARACETAMOL or PSEUDOEPHEDRINE or any of the other ingredients _(listed in section 6)_. If you have HIGH BLOOD PRESSURE or HEART DISEASE If you have DIABETES If you have PHAEOCHROMOCYTOMA (a tumour which affects your heart rate and blood pressure). If you have an OVERACTIVE Leer el documento completo
Health Products Regulatory Authority 12 August 2021 CRN00CFXF Page 1 of 2 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Non-drowsy Sinutab Tablets Paracetamol 500mg Pseudoephedrine hydrochloride 30mg. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 30 mg pseudoephedrine hydrochloride and 500 mg paracetamol. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Tablet _Product imported from the UK:_ White round biconvex tablet. 4 CLINICAL PARTICULARS As per PA0330/038/001 5 PHARMACOLOGICAL PROPERTIES As per PA0330/038/001 6 PHARMACEUTICAL PARTICULARS 6.1 LIST OF EXCIPIENTS Microcrystalline cellulose Pregelatinised maize starch Crospovidone Sodium starch glycolate (type A) Povidone Stearic acid Magnesium stearate 6.2 INCOMPATIBILITIES Not applicable 6.3 SHELF LIFE The shelf-life expiry date of this product is the date shown on the container and outer carton of the product as marketed in the country of origin. 6.4 SPECIAL PRECAUTIONS FOR STORAGE Store below 25 ˚C. Store in the original package. 6.5 NATURE AND CONTENTS OF CONTAINER Opaque white PVC and PVDC/Aluminium foil blister. Packs of 15 tablets Health Products Regulatory Authority 12 August 2021 CRN00CFXF Page 2 of 2 6.6 SPECIAL PRECAUTIONS FOR DISPOSAL No special requirements. Any unused product or waste material should be disposed of in accordance with local requirements. 7 PARALLEL PRODUCT AUTHORISATION HOLDER PCO Manufacturing Ltd. Unit 10, Ashbourne Business Park Rath Ashbourne Co. Meath Ireland 8 PARALLEL PRODUCT AUTHORISATION NUMBER PPA0465/184/001 9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 8th September 2006 Date of last renewal: 8th September 2011 Date of last review: January 2014 Last updated: August 2016 Last updated: August 2018 Last updated: October 2020 10 DATE OF REVISION OF THE TEXT August 2021 Leer el documento completo